Letter to Editor

Letter to Editor on CRISPR-Cas9 genome editing and Nobel Prize

Volume: 3 Number: 1 January 31, 2021
EN

Letter to Editor on CRISPR-Cas9 genome editing and Nobel Prize

Abstract

The countless applications of CRISPR-Cas9 genetic scissors are benefiting all of us in our research centres and we will most probably continue to benefit from this technology in the future. However, there are still questions that need to be answered: what will happen with the human genome editing in the long run? When will genome editing be proven to be safe and efficient to be used in editing human embryos? How many more experiments are necessary to be done on embryos to get an answer? Are there going to be rules and authorization in using gene-therapy kits in human genome editing, to prevent misuse of the technology? When will CRISPR-based gene editing be routinely used in clinic? We still need more time to get an answer to these questions and learn more about this technology. Let’s see together what surprising outcomes will genome editing science CRISPR-Cas9 bring us.

Keywords

References

  1. Ernst, M. P., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A. T., & Pijnappel, W. P. (2020). Ready for repair? Gene editing enters the clinic for the treatment of human disease. Molecular Therapy-Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2020.06.022.
  2. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., ... & Ho, T. W. (2020). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2031054.
  3. Ledford, H., & Callaway, E. (2020). Pioneers of revolutionary CRISPR gene editing win chemistry Nobel. Nature, 586(7829), 346-347. https://doi.org/10.1038/d41586-020-02765-9.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Letter to Editor

Publication Date

January 31, 2021

Submission Date

December 29, 2020

Acceptance Date

January 9, 2021

Published in Issue

Year 2021 Volume: 3 Number: 1

APA
Heta, E. (2021). Letter to Editor on CRISPR-Cas9 genome editing and Nobel Prize. Aurum Journal of Health Sciences, 3(1), 1-2. https://izlik.org/JA63LY73ZB
AMA
1.Heta E. Letter to Editor on CRISPR-Cas9 genome editing and Nobel Prize. AJHS-A. J. Health. Sci. 2021;3(1):1-2. https://izlik.org/JA63LY73ZB
Chicago
Heta, Eriona. 2021. “Letter to Editor on CRISPR-Cas9 Genome Editing and Nobel Prize”. Aurum Journal of Health Sciences 3 (1): 1-2. https://izlik.org/JA63LY73ZB.
EndNote
Heta E (January 1, 2021) Letter to Editor on CRISPR-Cas9 genome editing and Nobel Prize. Aurum Journal of Health Sciences 3 1 1–2.
IEEE
[1]E. Heta, “Letter to Editor on CRISPR-Cas9 genome editing and Nobel Prize”, AJHS-A. J. Health. Sci., vol. 3, no. 1, pp. 1–2, Jan. 2021, [Online]. Available: https://izlik.org/JA63LY73ZB
ISNAD
Heta, Eriona. “Letter to Editor on CRISPR-Cas9 Genome Editing and Nobel Prize”. Aurum Journal of Health Sciences 3/1 (January 1, 2021): 1-2. https://izlik.org/JA63LY73ZB.
JAMA
1.Heta E. Letter to Editor on CRISPR-Cas9 genome editing and Nobel Prize. AJHS-A. J. Health. Sci. 2021;3:1–2.
MLA
Heta, Eriona. “Letter to Editor on CRISPR-Cas9 Genome Editing and Nobel Prize”. Aurum Journal of Health Sciences, vol. 3, no. 1, Jan. 2021, pp. 1-2, https://izlik.org/JA63LY73ZB.
Vancouver
1.Eriona Heta. Letter to Editor on CRISPR-Cas9 genome editing and Nobel Prize. AJHS-A. J. Health. Sci. [Internet]. 2021 Jan. 1;3(1):1-2. Available from: https://izlik.org/JA63LY73ZB